# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Jones Trading analyst Soumit Roy initiates coverage on Editas Medicine (NASDAQ:EDIT) with a Buy rating and announces Price T...
Barclays analyst Gena Wang maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and lowers the price target from $9 t...
Truist Securities analyst Joon Lee maintains Editas Medicine (NASDAQ:EDIT) with a Buy and lowers the price target from $20 t...
B of A Securities analyst Greg Harrison upgrades Editas Medicine (NASDAQ:EDIT) from Neutral to Buy and raises the price targ...